| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/13/2002 | WO2002046152A2 Coniosetin and derivatives thereof, method for producing the same and use thereof |
| 06/13/2002 | WO2002046148A1 Substituted anthranilic acids |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002046144A1 Tetralone derivatives as antitumor agents |
| 06/13/2002 | WO2002046141A2 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002046138A2 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | WO2002046134A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | WO2002045800A2 Liquid composition comprising an alcohol |
| 06/13/2002 | WO2002045753A2 Oral extended release formulation of gepirone |
| 06/13/2002 | WO2002045751A1 Compositions for the treatment of coccidiosis |
| 06/13/2002 | WO2002045750A1 Combination drugs |
| 06/13/2002 | WO2002045749A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | WO2002045748A1 Ocular tension-lowering compositions for topical administration |
| 06/13/2002 | WO2002045742A2 Lipoteichoic acid immunogenic compositions and methods of making and using thereof |
| 06/13/2002 | WO2002045740A1 Compositions containing gangliosides for use in the treatment of skin disorders |
| 06/13/2002 | WO2002045737A2 Methods of treatment involving human mda-7 |
| 06/13/2002 | WO2002045720A1 Treatment of cancer by reduction of intracellular energy and pyrimidines |
| 06/13/2002 | WO2002045719A1 Remedies for hibernation-like symptom and agents inducing or relieving hibernation-like symptom |
| 06/13/2002 | WO2002045718A1 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
| 06/13/2002 | WO2002045717A1 Lometrexol combination therapy |
| 06/13/2002 | WO2002045716A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | WO2002045715A1 Nootropic effect enhancer |
| 06/13/2002 | WO2002045714A1 Drug formulation having improved oral tolerability |
| 06/13/2002 | WO2002045713A2 Orally-bioavailable formulations of fentanyl and congeners thereof |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002045710A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | WO2002045709A1 Clear propofol compositions |
| 06/13/2002 | WO2002045708A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | WO2002045707A2 Polynucleotide intercalator interceptors and inhibitors |
| 06/13/2002 | WO2002045706A2 The use of polymers for inactivating pathogens |
| 06/13/2002 | WO2002045705A2 Regenaration of blood vessels |
| 06/13/2002 | WO2002045704A2 Prevention and treatment of tachyphylactic response |
| 06/13/2002 | WO2002045703A2 Mixtures or organic compounds for the treatmentof airway diseases |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002045699A2 Transdermal therapeutic system comprising the active ingredient oxybutynin |
| 06/13/2002 | WO2002045696A1 Drug delivery system |
| 06/13/2002 | WO2002045695A2 Hydrostatic delivery system for controlled delivery of agent |
| 06/13/2002 | WO2002045694A1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045693A1 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 06/13/2002 | WO2002045692A1 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045688A2 Composition for treatment of inflammatory disorders |
| 06/13/2002 | WO2002045687A2 Topical alcoholic solution of a salicylic acid derivative and acemannan |
| 06/13/2002 | WO2002045686A2 Pharmaceutical paste comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045682A1 Particulate inhalation carrier |
| 06/13/2002 | WO2002045681A2 Solid polyunsaturated fatty acid compositions |
| 06/13/2002 | WO2002045658A2 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 06/13/2002 | WO2002045652A2 Tyrosine kinase inhibitors |
| 06/13/2002 | WO2002045590A1 Method for regional administeration of preparations for curing liver tumors |
| 06/13/2002 | WO2002045569A2 Method for precipitating red blood cells |
| 06/13/2002 | WO2002045525A2 Aged companion pet diet |
| 06/13/2002 | WO2002045509A1 A novel anti-fertility agent |
| 06/13/2002 | WO2002030906B1 Anti-tumour compounds |
| 06/13/2002 | WO2002028842A3 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 06/13/2002 | WO2002028825A3 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 06/13/2002 | WO2002028348A3 Compositions and methods for treatment of cystic fibrosis |
| 06/13/2002 | WO2002028270A3 The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor |
| 06/13/2002 | WO2002026218A3 Fatty acid analogues for the treatment of proliferative skin disorders |
| 06/13/2002 | WO2002024701A3 Substituted azepino[4,5b)indole derivatives |
| 06/13/2002 | WO2002024700A3 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES |
| 06/13/2002 | WO2002024686A3 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| 06/13/2002 | WO2002022204A3 Transdermal electrotransport device and method for manufacturing same |
| 06/13/2002 | WO2002022130A3 Means for regulating immune defences |
| 06/13/2002 | WO2002020012A3 Method for treating allergies using substituted pyrazoles |
| 06/13/2002 | WO2002020011A3 A method for treating allergies using substituted pyrazoles |
| 06/13/2002 | WO2002019996A3 Prevention of acute sinusitis and sinus attack |
| 06/13/2002 | WO2002019967A3 Substituted hydrazine derivatives |
| 06/13/2002 | WO2002018353A3 Oxazolidinone chemotherapeutic agents |
| 06/13/2002 | WO2002017854A3 Cephalosporin antibiotics and prodrugs thereof |
| 06/13/2002 | WO2002015891A3 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 06/13/2002 | WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 06/13/2002 | WO2002014315A3 Substituted pyrazoles |
| 06/13/2002 | WO2002012245A3 Azabicyclic derivatives and their therapeutic use |
| 06/13/2002 | WO2002011751A3 Combinations of dalfopristine/quinupristine with cefpirome |
| 06/13/2002 | WO2002009710A3 Paroxetine tablets and capsules |
| 06/13/2002 | WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 06/13/2002 | WO2002007712A3 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 06/13/2002 | WO2002006286A3 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 06/13/2002 | WO2002006221A3 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
| 06/13/2002 | WO2002004449A3 Methods for treatment of conditions affected by activity of multidrug transporters |
| 06/13/2002 | WO2002004404A3 7,8 and 9-substituted tetracycline compounds |
| 06/13/2002 | WO2002003998A3 Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| 06/13/2002 | WO2002003962A3 Drug delivery system for poorly water soluble drugs |
| 06/13/2002 | WO2002000657A3 Condensed pyrazindione derivatives |
| 06/13/2002 | WO2001098297A3 A thiazine oxazolidinone |
| 06/13/2002 | WO2001098277A3 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 06/13/2002 | WO2001097618A3 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 06/13/2002 | WO2001096879A3 Method and apparatus for monitoring anti-platelet agents |
| 06/13/2002 | WO2001096330A3 Thrombin receptor antagonists |
| 06/13/2002 | WO2001095884A3 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 06/13/2002 | WO2001091775A3 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 06/13/2002 | WO2001090159A3 Compositions and methods for delivery of a molecule into a cell |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001089554A3 Treatment of acute coronary syndrome with glp-1 |
| 06/13/2002 | WO2001089533A3 Preparation for stabilizing the protective layer on the epithelium of the cornea or the alveoli |
| 06/13/2002 | WO2001087981A3 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 06/13/2002 | WO2001085257A3 Opioid antagonist compositions and dosage forms |
| 06/13/2002 | WO2001085158A3 Anandamide and structurally related lipids as vanilloid receptor modulators |
| 06/13/2002 | WO2001085145A3 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 06/13/2002 | WO2001083438A3 New gamma selective retinoids |
| 06/13/2002 | WO2001079198B1 Pyrazoles for inhibiting protein kinase |